Teprotumumab as a novel treatment for pretibial myxoedema

Abstract

2 weeks, both in percentage change and in absolute value of the change.Ixekizumab induced immediate improvement in inflammatory markers in patients with GPP with systemic inflammation. This indicates that ixekizumab is a good treatment option for patients in the acute phase or in a flare of GPP, and that its effectiveness can be expected after a few days. Although BT seemed to decrease 1 day after initiation of ixekizumab, no significant difference was observed. The use of antipyretics may have affected the results. GMA is an extracorporeal circulation therapy that removes activated granulocytes and monocytes. It can be easily introduced in clinics and hospitals where haemodialysis is performed. Its safety profile 5 allows for its administration without screening and for its concomitant use with other therapies. GMA is usually not used as monotherapy but, rather, as adjuvant or neoadjuvant therapy for GPP. We previously reported that GMA induced a significant decrease in BT but not in WBC count or CRP after 2 days, 6 suggesting that GMA could be a good adjuvant therapy with ixekizumab. The main limitation of this study is that ixekizumab was not used as monotherapy.

Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion

“…A similar mechanism may effect thyroid dermopathy; several previous reports demonstrate response of dermopathy to IGF-1R inhibition. 5 , 6 , 7 , 8 Our patient had preexisting peripheral edema diagnosed as a component of Hashimoto thyroiditis which severely worsened during the Graves episode. While the characterization of this worsening edema is incomplete in the absence of formal dermatologic and radiographic evaluation, photographic documentation is presented.…”

“…Case reports have demonstrated response of thyroid dermopathy to the standardized dosing regimen. 5 , 6 , 7 , 8 We present a case of rapid improvement in symptoms of TED and amelioration of worsening peripheral edema and acropathy (not to be confused with acropachy) after treatment with teprotumumab.…”

Tofacitinib Treatment for Pretibial Myxedema

“…Topical and intralesional steroids may be beneficial for mild PTM but are not consistently successful in preventing PTM progression . Case reports and series have shown that teprotumumab, an inhibitor of the insulinlike growth factor 1 receptor, is effective in improving PTM . However, teprotumumab has high cost and low availability in some countries, including China; thus, economical and effective treatments are still needed.…”

Teprotumumab-associated hearing-related adverse events

“…3,4 Several other publications were excluded from further review based on irrelevance to our study topic. [21][22][23] This search method resulted in 3 clinical trials, 2 observational studies, 1 cohort, 6 individual case reports, and 3 case series included in this literature review for further data collection.…”